Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-118 in combination with standard therapy for newly-diagnosed Ph+ ALL
NCT07614022Phase 1Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LP-118 in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Wake Forest University Health Sciences. Primary endpoints: Maximum Tolerated Dose at 21 days and Recommended Phase 2 Dose at 21 days. Planned start Dec 2026; status: recruiting.
02
Drugs
LP-118
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT07614022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614022.